ExpreS2ion Biotech Holding AB publishes memorandum in advance of the Initial Public Offering

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes the memorandum for the Initial Public Offering which the company plans to  commence on June 8, 2016, in connection with the planned listing on Nasdaq Stockholm First North. The subscription period runs until June 22, 2016.

The Memorandum, which as of today is available in Swedish at the company’s (www.expres2ionbio.com) and Sedermera Fondkommission’s (www.sedermera.se) respective websites, contains a complete description of the company and its activities, the complete terms and instructions for the planned Initial Public Offering as well as a description of the risks that potential investors should consider along with the company’s growth opportunities. Teaser and subscription form will be published at the company’s and Sedermeras Fondscommision’s respective websites, when the subscription period commences.

Planned information meetings

In connection with the Initial Public Offering, ExpreS2ion will participate in the information meetings below, in order to inform about the company’s activities and future plans: 

For further information about the investor meetings, please contact Sedermera Fondkommission.

Financial Advisors and Certified Advisor

Sedermera Fondkommission is the financial advisor for ExpreS2ion in connection with the planned Initial Public Offering and listing on Nasdaq Stockholm First North. Sedermera Fondkommission is also appointed as Certified Adviser for the company.

For further information about the Initial Public Offering and listing, please contact:

Sedermera Fondkommission
Phone: +46 (0) 431 - 47 17 00
E-mail: info@sedermera.se

For further information about ExpreS2ion, please contact:

Steen Klysner, CEO
Telefon: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.

Tags: